Launch of Neuropad for treatment of diabetic foot syndrome announced

65

Masters Speciality Pharma, a UK-headquartered pharmaceutical company “specialising in the global distribution of high-quality, life-changing medicines”, has announced the launch of Neuropad, a rapid and reliable screening test for diabetic foot syndrome, in Brazil.

According to a statement, diabetes is growing at an alarming rate worldwide. In Brazil, over 12.4 million adults have diabetes, which accounts for 6% of the entire population of Brazil and 3% of the global diabetic population.

Diabetic foot syndrome arises from peripheral neuropathy in the foot as a result of diabetes. Peripheral neuropathy may affect up to half of diabetic patients and can lead to foot ulceration and, in severe cases, amputation. Early identification of the condition is crucial for effective treatment but due to nerve damage the condition can be difficult to detect.

Commenting on the launch, Zulf Masters, founder and CEO of Masters, said: “Foot ulceration is currently the leading cause of hospitalisation among people with diabetes. Reliable, early detection and continuous monitoring is the key to avoiding serious complications and the resulting human and economic consequences of treatment failure.

“Neuropad provides a simple, cost effective solution to patients in Brazil, and is a further example of Masters’ established capability of providing innovative, life-improving medicines to patients in underserved markets.”

Neuropad was developed by the German company TRIGOcare International GmbH and works by rapidly detecting the level of moisture in the feet. Reduced moisture from the sweat glands is associated with sub-motor dysfunction, an early sign of peripheral diabetic neuropathy.

As an adhesive pad impregnated with anhydrous cobalt II chloride, that is applied to the sole of each foot and indicates adequate sweat production by means of a blue (dry) to pink (moist) colour change, Neuropad is non-invasive, painless and can be administered at-home or in-clinic, providing a result in 10–15 minutes.

The clinical efficacy of this simple screening test has been determined in >40 clinical studies involving >3000 diabetic patients, and multivariate statistical analysis has shown that diabetic patients with an abnormal Neuropad result were 16 times more likely to develop foot ulceration compared with those having a normal result.

LEAVE A REPLY

Please enter your comment!
Please enter your name here